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AbstrAct
Objectives Despite continuous efforts to improve 
influenza vaccination coverage, uptake among high-
risk groups remains suboptimal. We aimed to identify 
policy amenable factors associated with vaccination 
and to measure their importance in order to assist in the 
monitoring of vaccination sentiment and the design of 
communication strategies and interventions to improve 
vaccination rates.
Setting The USA, the UK and France.
Participants A total of 2412 participants were surveyed 
across the three countries.
Outcome measures Self-reported influenza vaccination.
Methods Between March and April 2014, a stratified 
random sampling strategy was employed with the 
aim of obtaining nationally representative samples in 
the USA, the UK and France through online databases 
and random-digit dialling. Participants were asked 
about vaccination practices, perceptions and feelings. 
Multivariable logistic regression was used to identify 
factors associated with past influenza vaccination.
Results The models were able to explain 64%–80% 
of the variance in vaccination behaviour. Overall, 
sociopsychological variables, which are inherently 
amenable to policy, were better at explaining past 
vaccination behaviour than demographic, socioeconomic 
and health variables. Explanatory variables included 
social influence (physician), influenza and vaccine risk 
perceptions and traumatic childhood experiences.
Conclusions Our results indicate that evidence-based 
sociopsychological items should be considered for 
inclusion into national immunisation surveys to gauge 
the public’s views, identify emerging concerns and thus 
proactively and opportunely address potential barriers 
and harness vaccination drivers.
Background
Upper respiratory tract infections are a 
leading cause of mortality and morbidity 
in high-income countries, mostly among 
adults.1 Influenza is a major contributor to 
this burden of disease; estimates show that up 
to 49 000 people die every year in the USA2 
and 40 000 in the European Union3 from 
influenza-related illness.
In most developed economies, an annual 
influenza vaccine is recommended and 
offered free of charge to those at higher 
risk of death from influenza complications, 
including pregnant women, individuals with 
eligible chronic illnesses and people aged 65 
years and older. The vaccine is also available 
at a cost—usually in pharmacies or private 
healthcare facilities—to those who do not 
belong to a risk group, but wish to protect 
themselves. In the USA, for example, where 
the vaccine is recommended to all adults, 
approximately one-third of healthy adults 
under 65 years old vaccinate against influenza 
every year.4
Despite continuous efforts to improve influ-
enza vaccination coverage, uptake among 
high-risk groups remains low. In 2013/2014, 
for example, 65% of older adults (≥65s) and 
46% of younger adults with eligible health 
conditions were vaccinated against influenza 
in the USA.4 In the same season, vaccination 
rates in the UK, one of the highest in Europe, 
were 73% in ≥65s and 53% in eligible under 
65s, both below the minimum 75% coverage 
recommended by the WHO.5 6 Worryingly, 
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Research
Strengths and limitations of this study
 ► We generated regression models comprised of a 
broad set of variables, most of which have been 
linked to vaccination behaviour.
 ► We also aimed to use representative samples of the 
population of interest in three different developed 
countries (the USA, the UK and France).
 ► The employed survey measures concerned the 
individual and conditioned perceptions on their 
vaccination status.
 ► Our research may have suffered from respondent-
related biases. For example, people for whom 
vaccination issues are particularly salient may have 
been more prone to participate.
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a 151% rise in excess winter deaths in England and 
Wales in 2014/2015, partly attributed to the circulation 
of a mutated A(H3N2) influenza strain which made the 
vaccine significantly less effective,7 alongside unseason-
able warm weather in 2015/2016, resulted in the lowest 
vaccination uptake in more than a decade.8 Vaccina-
tion decisions are shaped by a myriad factors, including 
demographic, socioeconomic and sociopsychological 
factors.9–12 The latter are of particular interest, given that 
they are inherently amenable to policy and interventions 
to change behaviour. Yet, few countries routinely collect 
data on people’s beliefs and perceptions towards vaccina-
tion, and those that do often use one open question (eg, 
‘Why didn't you get a flu shot last winter?’).13 Although 
cheaper and easier to administer, this form of enquiry 
does not take into account people’s tendency to fall back 
on readily available information (eg, the first thought 
that comes to mind) or report postdecisional rationalisa-
tions of their behaviours (eg, ‘I did not vaccinate, hence 
it must not be necessary’) rather than actual drivers.14 15 
Moreover, these data do not allow comparative analyses 
between vaccinated and unvaccinated people.
Multilateral efforts to measure and improve confidence 
in vaccines are gathering pace,16 17 yet they are built 
upon a body of evidence which, although extensive and 
insightful, has a number of gaps. One key limitation is 
that many studies evaluating the link between sociopsy-
chological factors and influenza vaccination do not use 
multivariable analysis, thus the importance of a given vari-
able in relation to others often remains unknown. Studies 
that do employ multivariable analysis seldom perform (or 
report) robustness checks and usually comprise a limited 
number of variables, which can result in omitted-vari-
able bias, where the model compensates for the missing 
variables by over or underestimating the effect of the 
included variables.9 18 19 For example, omitted-variable 
bias could explain why the model developed by Weinstein 
et al—comprised of seven variables—showed that antici-
pated regret of not vaccinating was more important than 
other established influenza perceptions or why they did 
not find an association between vaccine effectiveness and 
vaccination uptake in this US sample.18 Moreover, these 
studies frequently include proxies of vaccination uptake, 
such as historical vaccination (ie, vaccination in previous 
seasons not including the most recent) in the case of 
retrospective studies or intention to vaccinate in the case 
of prospective studies, as independent variables,9 19 20 
thereby artificially boosting the explanatory ability of the 
model—because most people who vaccinate against influ-
enza do so periodically—without necessarily explaining 
vaccination behaviour (eg, people vaccinate because they 
feel vulnerable and/or receive a reminder from their 
general practitioner (GP) every winter). As Brewer and 
colleagues note, other important methodological short-
comings are the prevalent use of weak survey measures 
(eg, generic risk perceptions rather than own perceived 
risk) and small convenience samples, which may affect 
the validity and generalisability of findings.11 A related 
drawback is that most of the evidence in this area is 
produced in the USA, thus important contextual issues 
remain unexplored. Furthermore, vaccination coverage 
and factors underpinning uptake among healthy adults 
are often unknown.
We sought to address these limitations by generating 
regression models comprised of a broad set of variables, 
most of which have been linked to vaccination behaviour, 
by employing measures that gauge individuals’ own 
perceived risk (eg, ‘The flu could make me severely ill’) 
and condition their perceptions upon having or not 
having received the vaccine (eg, ‘With no flu vaccine, I 
would feel very vulnerable to the flu’),11 and aiming to 
use representative samples of the population of interest 
in three different developed countries: the USA, the UK 
and France. In order to assist in the monitoring of vacci-
nation sentiment and the prioritisation and design of 
communication strategies and interventions to increase 
influenza vaccination across different contexts, this study 
aimed to answer three research questions: (1) What are 
the variables that consistently explain recent influenza 
vaccination uptake? (2) What is the importance of policy 
amenable factors in relation to demographic, socio-
economic and health characteristics in explaining past 
vaccination behaviour? (3) Are the factors associated with 
influenza vaccination comparable across countries?
MeThods
study sample
Using stratified random sampling, we aimed to survey 
nationally representative adult samples from the USA, the 
UK and France, about vaccination between March and 
April 2014. Interlocking quotas based on gender, age and 
income were set. In addition, to ensure national repre-
sentativeness, regional, settlement type (rural/urban) 
and ethnicity non-interlocking quotas were put in place.
Since some of the included variables had not been previ-
ously tested and others were not consistently correlated 
with vaccination in previous studies, we assumed that the 
correlation coefficient between dependent and indepen-
dent variables was 0.1 (a small effect size), the minimum 
sample was calculated to be 782 subjects per country 
(α=0.05; 1-β=80%) with PASS V.11.
The American Institutes for Research (USA) and the 
Imperial College Research Ethics Committee (UK) 
granted research ethics approval. The French Commis-
sion nationale de l'informatique et des libertés and 
Comités de protection des personnes granted waivers to 
approval. Participants were informed about the nature of 
the study and provided consent.
Procedure
A market research company (Double Helix) was respon-
sible for piloting, programming the online survey and 
conducting the telephone interviews. Ten pilot inter-
views (seven face-to-face and three telephone interviews) 
were conducted with purposively selected participants in 
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the UK to test the survey’s face and content validity, and 
ease of completion. Additionally, 10 pilot interviews were 
conducted over the phone in the USA and 10 in France 
with the aid of a screen sharing platform. Interviews were 
conducted by a trained researcher while the rest of the 
team observed via live broadcast. The pilot showed the 
survey was easy to complete and understand, and lasted 
approximately 20 min. The refinements to the study mate-
rials were related to wording and format. Self-completion 
online surveys were then sent to a non-probability online 
panel and random-digit dialling was employed to recruit 
a proportion of the 65+ age category and those belonging 
to D/E socioeconomic groups, due to their limited access 
to or lack of familiarity with internet-based applications21 
(see online supplementary box S1 for more details about 
non-probability online panels).
As a quality control measure, participants classified as 
‘speeders’ (completed the survey in half of the average 
length—16 min) and ‘flat-liners’ (gave homogenous 
responses and completed the survey in less than half of 
the optimum survey length—20 min) were removed and 
replaced.22
Instrument
The measures reported here are a subset of a larger vacci-
nation survey (available from the authors upon request). 
Our analyses included 32–34 items (see online supple-
mentary table S1). We selected sociopsychological items 
that had been linked to influenza vaccination based on 
existing evidence. These comprised adapted constructs 
from the Health Belief Model23 and Protection Moti-
vation Theory24—notably, influenza and vaccine risk 
perceptions, vaccine effectiveness and self-efficacy,9–12 25 
perceived knowledge of the vaccine10 and items assessing 
trust in key vaccination stakeholders.26 Additional policy 
amenable factors which had infrequently been used in 
the context of vaccination, but were considered potential 
explanatory variables, were also tested. These were worry 
of infecting other people (if unvaccinated)27—a measure 
aimed at evaluating the extent to which people vaccinate 
to protect others, perceived control over influenza,28 29 
regret of contracting influenza,30 childhood traumatic 
health experiences31—to evaluate their influence on 
adult vaccination behaviour, and health decision-making 
preferences32 33—to further explore the effect of the 
doctor–patient relationship on vaccination acceptance. 
Participants’ socioeconomic, demographic and health 
characteristics previously associated with influenza vacci-
nation were prioritised.9 34
We used 11-point Likert scales (0–10) for the majority 
of sociopsychological items, as these are recognised for 
their reliability and ease of completion,35 and multi-
ple-choice items and alternate-choice items when 
appropriate. Except for trust, health decision-making 
preferences and childhood traumatic health experi-
ences items, sociopsychological measures were disease or 
vaccine specific to avoid misinterpretation. As illustrated 
in the introduction, our questions also aimed to capture 
the respondent’s perception of their own personal risk 
rather than their views on risk of illness in the wider 
population. Thus, we asked how likely it is that they 
might become ill rather than how likely people generally 
are to get influenza. We also wished to specifically focus 
their attention on the risk of influenza in the presence 
or absence of vaccination, as people may feel more or 
less protected depending on their vaccination status. 
The questions were therefore in the form of ‘Without 
a vaccine, it is likely I will get the flu’ rather than simply 
assessing their views on the likelihood of getting influ-
enza. Finally, when thematic hierarchy (eg, from general 
to specific) was not important, items were rotated to 
minimise response bias.
data analysis
We used the following formula to calculate response rates: 
number of surveys completed divided by sent emails or 
interviews attempted minus ineligible individuals, multi-
plied by 100. Descriptive statistics, Pearson’s χ2 test and 
t-tests were computed to explore the relationships between 
the assessed variables and self-reported past vaccination 
behaviour. Point-biserial correlations were calculated and 
χ2 statistics were converted into correlation coefficients 
to explore whether the relationship between the depen-
dent and independent variables matched or exceeded a 
coefficient of 0.1—the assumption employed to calculate 
the sample size. Cronbach’s alpha was used to explore the 
reliability of the proposed measures across countries. The 
outcome measure was receiving an influenza vaccine in 
the last 6 months (2013/2014 influenza season).
Given that the dependent variable was binary, logistic 
regression analysis was conducted to identify the vari-
ables associated with past influenza vaccination. Four 
continuous variables with ‘I don’t know/not applicable’ 
responses were dichotomised as follows: values expressing 
agreement with a given statement (6–10) were coded as 
1=‘yes’ and the rest (0–5 and ‘I don’t know/not appli-
cable’) were coded as 0=‘other than yes’ (see online 
supplementary tables S2–S4).
Although a software-based stepwise approach is widely 
used in logistic regression, in recent years the purposeful 
selection of variables has been favoured over determin-
istic model-building methods. This is because the latter 
tend to rely on automatic selection of variables based only 
on mathematical criteria, which can lead to overfitting or 
underfitting models. Therefore, we used a manual step-
wise, hierarchical approach, where blocks of variables were 
entered in a sequence based on previous evidence and our 
aim of assessing the importance of policy amenable factors 
in explaining influenza vaccination (see online supplemen-
tary box S2 for a full description of the approach).36
Two goodness-of-fit tests—χ2 and Nagelkerke R²—were 
used to assess the overall model (M1) and each of the 
seven models (blocks) generated using the hierarchical 
approach. Employing a classification cut-off point of 0.5, 
a final model with a Nagelkerke R² value close to 1, which 
indicates optimal model fit, was sought.
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Thorough checks to ensure the robustness of the 
models were conducted, including variance inflation 
factor (VIF) to assess collinearity, standardised residuals 
to detect and evaluate outliers and Cook’s distance to 
identify influential cases. Separate analyses entering the 
blocks of variables in reverse order were also performed 
(ie, from block 7 to block 1) to evaluate whether the order 
in which variables were entered significantly modified our 
results. Data were analysed using IBM SPSS Statistics V.22.
resulTs
Participants
The online survey was completed by 814 partici-
pants in the USA, 791 in the UK and 787 in France. 
Online response rates were low (USA=1%; UK=1.7%; 
France=2.4%), although consistent with research on 
non-probability online panels showing that, in recent 
years, response rates have fallen to a point where in 
many cases they are 10% or less.37 Eighty participants 
were interviewed via the telephone in the USA, 100 in 
the UK and 100 in France. Telephone response rates 
were 6%–9%. Telephone interviews targeted older 
people and those belonging to low socioeconomic 
strata, two populations with particularly low response 
rates.38 Recruitment flow diagrams for the online and 
telephone samples are presented in online supplemen-
tary figures S1A–S3A and S1B–S3B, respectively.
Except for education in the USA—the sample was 
more educated than the general population, there were 
no significant differences between the characteristics of 
the final samples (USA=801; UK=806; France=805; total 
sample n=2412) and those of the general population, 
when available (table 1). To facilitate survey completion 
and improve data accuracy, household income data for 
this study were collected using a limited number of 
bands relevant to each country. Therefore, it cannot be 
directly compared against census data, which collects 
more granular income information per household. 
However, we have used as a reference the band that 
is most approximate to the census median household 
income (table 1). In the USA and the UK, roughly half 
of the sample was below the reference band and the 
other half was above; whereas in France, the number of 
participants who reported a household income below 
the median was substantially higher than those over the 
median (table 1).
Healthcare professionals were excluded from the final 
samples as their decision-making processes are influenced 
by those they care for or regulated by healthcare authori-
ties, thus some of their motivations and concerns may differ 
from those of the general population.39 Subgroup analyses 
confirmed these differences (available upon request).
differences between vaccinated and non-vaccinated 
participants
Overall, the responses of vaccinated and unvaccinated 
participants were significantly different (p<0.05–0.001) 
and comparable across countries (see online supplemen-
tary tables S2–S4). Those who had received an influenza 
vaccine were older, reported having an eligible health 
condition, had a private or public health insurance, lived 
with a partner (USA/France), were wealthier (USA/
France) and more educated (USA). They were also 
less constrained by practical barriers and more likely to 
report that their physician and relatives thought they 
should vaccinate than those who had not received a 
vaccine. Vaccinated participants were more concerned 
about the risks of influenza, less worried about the risks of 
the vaccine and more trusting of vaccine manufacturers 
and providers than unvaccinated participants. Vaccinees 
reported possessing a better understanding of the influ-
enza vaccine and were more prone to let physicians make 
decisions about their health (USA/UK) than those who 
had not vaccinated. Lastly, vaccinated participants were 
less likely to have had a bad vaccine or injection-related 
experience (UK) and more likely to have had a scary 
health-related experience in childhood than unvacci-
nated participants.
Factors associated with past influenza vaccination in 
regression analyses
When all variables were assessed concurrently, the models 
that best fitted the data (M6–M8) explained 73% of the 
variance in past vaccination behaviour in the USA, 80% in 
the UK and 64% in France (Nagelkerke R²=0.644–0.795) 
(tables 2–4). The first models (M1) included all the vari-
ables, thus were less parsimonious than M6–M8, yet they 
explained a similar share of the variance (66%–80%). 
When using the hierarchical approach, the first-step 
models (M2), which included demographic, socioeco-
nomic and health variables, fitted the data poorly to 
moderately and accounted for 22% of the variance in 
past vaccination behaviour in the USA, 38% in the UK 
and 19% in France. Practical barriers only explained 3% 
of the variance in the USA (M3) and were not significant 
in the UK and France. Social influence explained 14% 
of the variance in the USA (M4), 21% in UK and 25% 
in France (M3). Influenza perceptions accounted for 
30% of past vaccination behaviour in the USA (M5), 17% 
in the UK and 18% in France (M4), whereas influenza 
vaccine perceptions only explained 1% of this behaviour 
in the USA (M6), 2% in the UK and 1% in France (M5). 
Finally, trust items explained less than 1% of the variance 
in the USA, while decision-making preferences and child-
hood experiences explained 2% of the variance in the UK 
and 1% in France.
When blocks were entered in reverse order, 
demographic, socioeconomic and health variables 
contributed little to the variance in past vaccination 
behaviour—3% (USA), 1% (UK) and 0% (France). 
This is not surprising, since people’s characteristics 
have an effect on their perceptions, thus they explain 
some of the same variance. This result further proves 
that poorly specified models—which are not evidence 
based—lead to biased estimates (the detailed results 
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of these analyses are available from the corresponding 
author upon request).
Robustness checks showed that the variables which were 
significant in M1 remained significant across most 11–21 
specifications, with some exceptions. In the USA, ‘vaccine 
is painful’ became non-significant when non-significant 
influenza perceptions were removed. This suggests that 
the latter had a suppressor effect on the former, that is, 
their inclusion strengthened the effect of the variable 
in question.40 In the UK, gender became significant 
when non-significant vaccine perceptions were removed, 
and ‘vaccine transmits influenza’ became significant 
when ‘vaccine contents are dangerous’ was removed. 
In both cases, this indicates that the removed variables 
were confounders of those that became significant.41 In 
France, ‘trust in manufacturers’ was a confounder of 
education—the latter became significant in the absence 
of the former, and ‘trust in physician’ was a suppressor 
of ‘vaccine access’—the latter became non-significant 
when the former was excluded.41 42 Consequently, all the 
variables that were significant in M1, one non-significant 
variable that became significant while performing robust-
ness checks (‘vaccine transmits influenza’ in the UK) and 
all the controls were included in the hierarchical models. 
The magnitude and significance of the relationship 
between independent and dependent variables varied 
little between the first models (M1), where all the vari-
ables were entered at the same time, and the last models 
(M6–M8), where a reduced number of variables were 
entered in blocks, which is a further indication of the 
robustness of our findings. Detailed robustness checks 
are not presented here for brevity, but are available from 
the corresponding author upon request.
All the correlation coefficients between the dependent 
and the independent variables were higher than 0.1, 
except for two variables which were tested for the first 
time in this study: ‘Bad experience vaccines – child’ (r = 
−0.082, p<0.05 in the UK; r=0.040, p>0.05 in the USA; and 
r=−0.064, p>0.05 in France) and ‘Scary health experience 
– child’ (r=0.090, p<0.05 in the USA) (detailed results are 
available from the corresponding author upon request).
Cronbach’s alpha coefficients ranged from acceptable 
(α=0.65) to excellent (α=0.87) and they were compa-
rable across countries for each evaluated scale, except 
for ‘trust in vaccination stakeholders,’ which was consid-
erably less reliable in France (see online supplementary 
table S5). Overall, these results indicate that the scales 
worked in a similar manner across the three countries. 
Further psychometric analyses and scale refinement will 
be performed and reported in a separate article.
Collinearity diagnostics showed that all variables had VIF 
values below 5, indicating there is no cause for concern.43 
Standardised residuals were also examined to identify 
outliers. Less than 5% of the cases had standardised resid-
uals above 2 and no more than 1% had absolute values 
higher than 3, thus there was no need to eliminate or 
transform cases.44 Cook’s distance statistics were evalu-
ated to identify cases exerting excessive influence on the 
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model. No values were higher than 1, which shows that no 
case had to be excluded on that basis.45
dIscussIon
This study aimed to identify policy amenable factors asso-
ciated with recent influenza vaccination uptake among 
adults in three high-income countries and to quantify 
their impact. Our results support previous findings and 
add new insights.
The final models robustly explained 64%–80% of the 
variance in past vaccination behaviour and although some 
predictors were country specific, we found important 
commonalities (table 5). To the best of our knowledge, 
ours is the first study to demonstrate that sociopsycho-
logical variables consistently explain most of the variance 
in past influenza vaccination behaviour, over and above 
demographic, socioeconomic and health variables (49% 
vs 22% in the USA, 42% vs 38% in the UK and 45% vs 
19% in France). Our findings also show that the most 
important policy amenable factors were social influ-
ence, particularly physicians’ (USA=14%, UK=21% and 
France=25% of the variance) and perceptions about 
influenza (USA=30%, UK=17% and France=18% of the 
variance), communication efforts should, therefore, 
focus on these factors. Surprisingly, perceptions about 
the influenza vaccine explained a very small proportion 
of vaccination behaviour across the three countries. Addi-
tionally, our results show that a sizeable proportion of 
adults under the age of 65 years, both with and without 
eligible chronic conditions, is vaccinating against influ-
enza in the USA (over a third) and the UK (under a 
third), while only 16% do so in France.
Specifically, and in line with previous evidence, we 
found that age, health status, health insurance, income, 
gender, marital status and education were associated with 
past vaccination.9 34 Differences between countries are 
likely influenced by their healthcare systems and immu-
nisation policies.
For example, having an eligible health condition was 
more important than age on its own in the USA and the 
UK, whereas the opposite occurred in France. One plau-
sible reason is that a controversy about the effectiveness 
and safety of the A(H1N1)pdm09 vaccine in 2009/2010, 
which has had a lasting negative impact on seasonal influ-
enza vaccination rates in France, may have dissuaded 
some populations—such as younger people with and 
without eligible health conditions who may feel less 
vulnerable—more than others.34 46 This controversy may 
also be underpinning the differences in model variance 
and reliability of the trust scale found between France 
and the other two countries, both of which had not expe-
rienced important influenza vaccination scares in recent 
years, and hence, had maintained fairly constant vacci-
nation rates for more than a decade at the time of data 
collection.4 5 12 Private and public health insurance, and 
income were associated with past vaccination in the USA, 
a country with a largely privatised healthcare system. 
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Although the UK and France have healthcare systems 
which are free at the point of delivery or affordable for 
most, the influenza vaccine is only free of charge for high-
risk groups, which may explain the association between 
health insurance and past vaccination in both coun-
tries—although weak in France. Marital status was also 
correlated with past vaccination in the UK and France. 
Higher vaccination rates among participants living with a 
partner may be explained by people’s tendency to protect 
their significant other or encouragement from partners 
to get vaccinated, yet more evidence is needed to substan-
tiate this assertion. Finally, being male and more educated 
were positively associated with past vaccination in the UK 
and France, respectively. Yet, both characteristics were 
not robustly correlated with past vaccination across all 
specifications, and the association between gender and 
vaccination in the UK is weak, thus these findings should 
be interpreted with caution. Future research testing our 
findings across adequately powered samples of high-risk 
people will certainly improve our understanding of the 
relative importance of demographic, socioeconomic and 
health factors in vaccination decisions among eligible 
individuals. We hypothesise that sociopsychological 
factors are likely to be more pivotal and discriminant 
within high-risk groups, as characteristics such as age 
may be less predictive of vaccination in samples of over 
65s and health status may be less important in samples of 
younger people with eligible health conditions.
Our results also show that practical barriers were not 
important, except for time in the USA. This finding 
suggests that a culture of long working hours and short 
holidays may indeed have a negative effect on vaccination 
uptake.
Consistent with previous research, we found that 
physicians’ opinion (and relatives’ opinion in the 
UK), perceived vulnerability to and likelihood of influ-
enza (and severity of influenza measured in number of 
bed-days in the UK), perceived vaccine effectiveness (only 
in the USA), the perception that the vaccine transmits 
influenza (in the USA and UK) or that its contents are 
dangerous (France), and perceived vaccine-related self-ef-
ficacy (UK) were associated with vaccine uptake.9–12 25 As 
previously reported in the literature,11 we also found a 
small negative association between the perceived severity 
of influenza and past vaccination in the USA, and no 
association in the UK and France. A possible explana-
tion is that people who believe that influenza could 
make them severely ill, may also be concerned about 
the vaccine influenza-like symptoms, thus omission bias 
may induce them to refrain from vaccinating.31 47 Alter-
natively, the knowledge that influenza could be serious 
may not necessarily translate into a feeling of personal 
threat, particularly among younger individuals. A similar 
result was the lack of or negative association between 
perceived susceptibility to influenza and past vaccination 
in the USA and France, and the UK, respectively. These 
findings indicate that measuring perceived influenza 
severity as degree of seriousness (‘the flu could make me 
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Table 5 Survey items associated with past influenza vaccination
Item USA UK France
What is your date of birth? ✓
Have you ever been diagnosed with any of the following (eligible) conditions? ✓ ✓
Do you have a private health insurance? ✓ ✓ ✓
Do you have public health insurance (eg, Medicare)? ✓
What is your gender? ✓
Which of the following options best describe your current situation (marital status)? ✓ ✓
What is your combined annual household income? ✓
What is the highest level of education you have completed? ✓
  I can make time to get the flu vaccine. ✓
  My physician thinks I should get a flu vaccine. ✓ ✓ ✓
  My relatives or close friends think I should get a flu vaccine. ✓
  With no flu vaccine, I would feel very vulnerable to the flu. ✓ ✓
  If I got the flu, I would feel sicker than other people my age. ✓
  Without a flu vaccine, I am sure I would get the flu this winter. ✓ ✓ ✓
  I believe that if I got the flu I would have to stay in bed for… ✓
  The flu could make me severely ill. ✓
  If I don’t get the flu vaccine and I get the flu, passing the flu to other people would worry me 
because it would be my fault.
✓
  I am confident I can avoid getting the flu, even without the flu vaccine. ✓ ✓ ✓
  If I don’t get a flu vaccine and end up getting the flu this winter, I would regret not getting the 
vaccine.
✓ ✓ ✓
  I feel I know enough about the flu vaccine to make an informed decision about whether to get 
vaccinated or not.
✓ ✓
  If I get a flu vaccine, I will be protected against the flu. ✓
  The flu vaccine could give me the flu. ✓ ✓
  I am worried that some of the contents of the flu vaccine may be dangerous for me. ✓
  I am confident I can get a flu vaccine if I want one. ✓
Which of the following statements best represent how much you trust your physician? (Trust 
scale)
✓
How actively do you participate with your physician in making decisions about health, generally? 
(Health decision-making scale)
✓
  I had a bad experience with vaccines or injections. ✓
  I had a scary health-related experience. ✓ ✓ ✓
See the full list of included items and response categories in online supplementary table S1.
severely ill’) and perceived susceptibility to influenza as 
individuals’ constitutional vulnerability in relation to that 
of others (‘If I got the flu, I would feel sicker than other 
people my age’), does not improve our understanding of 
vaccination behaviour, as previously suggested.11
Interestingly, perceived vaccine knowledge (to make 
informed decisions) was negatively correlated with past 
vaccination in the USA and positively correlated in the 
UK. Researchers have long advocated for strategies to 
increase knowledge about vaccines,10 yet these results 
suggest that a cognitive approach may not always be 
effective, particularly when the target population (eg, 
USA unvaccinated people) perceive themselves as being 
knowledgeable, and hence are less likely to seek or be 
receptive to further information.
Factors which are less explored in the literature were 
also robustly correlated with past vaccination. Perceived 
control over influenza and regret of catching it (if unvacci-
nated) were significantly associated with past vaccination 
behaviour across the three countries. Worry of infecting 
other people (if unvaccinated) was only linked to past 
vaccination in the UK, but the direction of the association 
was unexpected: unvaccinated participants worried more 
than vaccinated participants of infecting other people if 
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they were to remain unvaccinated. Although this question 
was hypothetical, it is plausible that unvaccinated partici-
pants felt worried about infecting others because of their 
actual vaccination status, whereas vaccinated participants 
did not, either because they felt protected by the vaccine 
or they do not generally worry about infecting others. 
In any case, this result does not support the notion that 
altruism motivates people to vaccinate.27
Our results also show that trust in key vaccination 
stakeholders does not play a significant role in influenza 
vaccination decisions in these countries. In fact, we found 
that US vaccinees were less trusting of their physician than 
those who did not vaccinate. This finding conflicts with 
the premise that all vaccination decisions are a combina-
tion of individuals’ perceptions of the information they 
receive and their trust in those who manufacture, legis-
late and deliver vaccines.26
A striking finding from a qualitative study31 held true 
when tested quantitatively. UK participants who had 
a bad experience with needles in childhood were less 
likely to vaccinate later in life, consistent with evidence 
showing that traumatic experiences can linger through to 
adulthood and significantly influence health decisions.48 
This was further supported by the increased likelihood 
of vaccinating exhibited by those who reported a scary 
health-related experience in childhood across the three 
countries, although less so in the USA, possibly due to 
a lasting perception of vulnerability that resulted in 
enhanced preventive behaviours in adulthood. To our 
knowledge, this is the first quantitative study linking 
adult vaccination behaviour with childhood experiences. 
Therefore, further testing these results across different 
samples would be desirable to ensure that the link (or 
lack thereof) between these variables and influenza vacci-
nation is a true one. Additionally, future research could 
unpack this synergistic effect using qualitative approaches.
Finally, we found that UK vaccinees were more likely to 
let their doctors make decisions about their health. This 
finding resonates with findings from Opel and colleagues 
which showed that parents were more likely to resist 
advice if the doctor used a participatory (eg, ‘What do 
you want to do about shots?”) rather than a presump-
tive initiation approach (eg, ‘Well, we have to do some 
shots’).49 Researchers could test the replicability of Opel’s 
study on adult vaccination and further explore the role 
of health decision-making preferences on doctor–patient 
communication about vaccines.
Policy implications
This study offers evidence that can inform policy and prac-
tice. Sociopsychological factors associated with influenza 
vaccination can be used to track vaccination sentiment 
and forecast uptake. These factors are currently not 
consistently monitored and rarely used as a basis for 
effective service delivery and communication strategies. 
If we are to improve or at least sustain current immuni-
sation rates, we must start actively listening to the public 
by including these aspects into national immunisation 
surveys. An important challenge for policymakers is prior-
itising what to monitor and to what extent. As a first step, 
influenza vaccination surveillance systems should include 
the explanatory variables reported here, particularly 
those accounting for a significant proportion of the vari-
ance in vaccination behaviour (ie, social influence and 
influenza perceptions), and make additions or adjust-
ments over time.
More importantly, our findings suggest that sociopsy-
chological factors could provide a valuable opportunity to 
develop and evaluate targeted interventions to improve 
vaccination coverage. For instance, the influence of physi-
cians’ opinions on vaccination, over and above people’s 
trust in immunisation stakeholders (including physicians 
themselves), indicates that improving communications 
at the practice level should be prioritised. One possible 
intervention is to reach undervaccinated groups (eg, 
younger eligible individuals) via consultations and vacci-
nation reminders, a strategy that has been successful in 
older populations.50 A complementary initiative is to 
link influenza vaccination rates to pay-for-performance 
systems, such as the UK Quality and Outcomes Frame-
work which rewards GPs for vaccinating some at-risk 
groups. Yet, further incentivising primary care practices to 
employ more effective approaches to reach out to eligible 
unvaccinated patients may require a stratified strategy 
that offers larger rewards for vaccinating subgroups 
with low vaccination rates and additional incentives for 
exceeding vaccination targets.51 However, we acknowl-
edge that the implementation of more complex incentive 
systems would require additional resources. In the USA, 
programmes to introduce the influenza vaccine in the 
workplace may encourage those with limited time to 
protect themselves.
Efforts could also focus on addressing the gap between 
perceived and real risks of influenza. This could be 
achieved by moving away from generic messages about 
the threat of influenza (eg, ‘influenza is serious’) towards 
tailored messages which take into consideration the 
needs and characteristics of different at-risk populations. 
For instance, influenza-related complications in young 
diabetics may differ from those experienced by elderly 
people. Specific messages may, therefore, allow individ-
uals and their families to better identify risks relevant to 
their condition and, in turn, compel them to vaccinate.
Similarly, effective communications as part of the 
consultation aimed at assuaging concerns around vaccines 
could take into account decision-making preferences and 
individual past experiences, particularly in the UK. For 
instance, communication efforts are likely to be better 
spent on those who prefer to make decisions about their 
heath independently than those who are more prone to 
delegate health decisions to their physician. Given the 
lasting effect of some traumatic childhood experiences, 
interventions and new products aimed at making all 
childhood encounters with injections as easy as possible 
may be a good investment in the success of vaccination 
programmes in the future.
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However, in a context of constrained resources, physi-
cians and nursing staff have limited time and resources 
to improve vaccination services and communications. 
Hence, increased investment in the provision of training, 
adequate communication materials and decision aids 
to enhance patient–doctor communication is urgently 
needed and much deserved.
Messages delivered in primary care settings could also 
be complemented with evidence-based mass communica-
tions. For example, a national campaign could combine 
messages about the risks of influenza (eg, likelihood of 
catching it and feelings of vulnerability and regret for not 
vaccinating) with messages about the limited protective-
ness of avoidance strategies (eg, taking vitamins or evading 
crowds), and provide—rather than avoid —easy-to-under-
stand and accurate information about vaccine safety (eg, 
communicating more effectively the difference between 
vaccine-induced symptoms and actual influenza symp-
toms) and effectiveness, particularly in the USA. When 
possible, mass communications should also be tailored to 
specific at-risk populations.
Finally, given that the influenza vaccine is more effec-
tive in healthy working adults52—reducing the number of 
influenza-like episodes among this population, but also 
providing indirect protection to at-risk groups, knowing 
what motivates them to vaccinate can be valuable to poli-
cymakers seeking to reduce the societal cost of influenza.
limitations
This study has several limitations, some of which may 
affect the generalisability of our findings. Although 
the use of non-probability online panels has become 
increasingly common,53 54 response rates are generally 
low.37 55 This is largely because online panel members 
become desensitised to survey email invitations from the 
online panel provider.55 56 However, an emerging body 
of evidence shows that higher response rates may not 
be associated with more accuracy, in fact, some studies 
have found that high response rates can yield less accu-
rate results.57 This suggests that the low response rates 
we achieved may not be as important a source of bias 
as using a sample drawn from a non-probability online 
panel. This is because the relationship between the 
sample and the non-probability online panel popula-
tion is often unknown, so it is not possible to estimate 
how representative the sample is of the population as 
a whole. Therefore, our research may have suffered 
from respondent-related biases; for example, people 
for whom vaccination issues are particularly salient may 
have been more prone to participate.56 Consequently, 
responses may have been more polarised, both in 
favour and against of vaccination. Future studies testing 
our findings using different sampling strategies, such 
as the use of probability online panels or random digit 
dialling, are warranted. A related limitation is that our 
US sample was more educated than the population, 
which may have affected the generalisability of our 
findings, although there is no consensus regarding the 
link between education and influenza vaccination in 
the USA.9 10 12 Similarly, in France, participants were 
less likely to disclose their household income and over 
half reported it to be equal or below the band that was 
closest to the median income of the population, which 
could also have biased our results. Further, since we 
sought to attain samples that were representative of the 
adult population, they may not have been adequately 
powered to detect subgroup differences (eg, whites vs 
non-whites).
Another possible drawback is that lengthy instruments 
may fatigue participants and affect the quality of the data. 
Although pilot results indicated that participants did not 
feel the survey was long or difficult to complete, there is a 
chance that those who did not finish the survey may have 
found it too lengthy. A related limitation is the dichoto-
misation of four continuous variables, which could have 
resulted in loss of information. However, on balance, this 
was deemed necessary to aid the analysis of survey items 
with numerous ‘I don’t know/not applicable’ responses, 
which are not the same as missing responses. Strategies 
used to deal with missing responses, such as imputation 
or case exclusion, would have been inappropriate or 
would have significantly reduced the size of our samples 
and affected their composition.
An additional limitation is the use of a subjective 
outcome measure. Although data from medical records 
may be preferable, previous research comparing the 
accuracy of the latter to self-reported influenza vaccina-
tion has shown these can coincide in up to 90% of the 
cases.58 Further, since some people vaccinate at work 
or alternative facilities such as pharmacies, it remains 
unclear whether medical records are more accurate than 
self-reports.
Lastly, although we employed a battery of measures 
designed to capture people’s actual perceptions about 
influenza and the influenza vaccine, using a prospec-
tive design and a representative sample of vaccine-naïve 
participants would have been preferable to avoid postde-
cisional rationalisations. However, this research design 
requires substantial financial resources and time which 
were not available to us, and hence, a retrospective 
design was chosen instead. Consequently, and consistent 
with other retrospective cross-sectional studies, causation 
cannot be inferred, thus some of the assessed perceptions 
may have been generated or reinforced by prior vaccina-
tion. Moreover, this study’s design precludes any attempt 
to predict future behaviours. Further research testing 
whether the identified explanatory variables prospec-
tively predict actual vaccination uptake among first-time 
vaccinees is merited.
conclusIons
This study identifies policy amenable factors associated 
with past influenza vaccination and presents a set of robust 
explanatory variables that aims to attain a comprehensive 
and more accurate understanding of the constellation of 
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factors underpinning vaccination behaviour. Our findings 
can prove useful for countries looking to improve vacci-
nation rates by developing more opportune and effective 
communication strategies and implementing evidence-
based interventions. Our results highlight the importance 
of routinely monitoring vaccination sentiment and using 
these data to inform immunisation policy.
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